General Statement of Disclosure:

CONSULTING FEES/HONORARIA: Novo Nordisk Inc.(MODEST), Milestone pharmaceuticals(MODEST) RESEARCH/RESEARCH GRANTS: Biocardia(SIGNIFICANT), CSL Behring LLC (CSLB)(SIGNIFICANT), LivaNova USA, Inc. (SIGNIFICANT), BIOTRONIK, INC.(SIGNIFICANT), Abbott(SIGNIFICANT), TIMI Study Group and AstraZeneca(SIGNIFICANT), Medtronic, Inc(SIGNIFICANT), Medtronic, Inc.(MODEST), Evaheart, Inc(SIGNIFICANT), Novartis(SIGNIFICANT), Abbott Laboratories(SIGNIFICANT), Ablative Solutions, Inc(SIGNIFICANT), XyloCor Therapeutics, Inc.(SIGNIFICANT), NIH(SIGNIFICANT), nih(SIGNIFICANT), AHA(SIGNIFICANT), PCORI(SIGNIFICANT), NIH(SIGNIFICANT), NIH(SIGNIFICANT), DOD(SIGNIFICANT) OTHER FINANCIAL BENEFIT: DCRI(MODEST)

View Full Disclosure